Showing results (91-100 of 217) with videos related to
Sort By:
Pageof 22
Gynecologic Oncology|December 9, 2014
A phase II trial of paclitaxel, carboplatin, and bevacizumab in advanced and recurrent endometrial carcinoma (EMCA)Fiona Simpkins, Richard Drake, Pedro F Escobar, et al.Gynecologic Oncology|November 9, 2010
An open-label, single-arm Phase II study of intravenous weekly (Days 1 and 8) topotecan in combination with carboplatin (Day 1) every 21 days as second-line therapy in patients with platinum-sensitive relapsed ovarian cancerPeter G Rose, Bradley J Monk, Diane Provencher, et al.Gynecologic Oncology Reports|December 9, 2020
Predictors of response to immune checkpoint inhibition in a real world gynecologic cancer populationMichelle L Kuznicki, Carrie Bennett, Meng Yao, et al.Immunotherapy|August 23, 2021
Immune cells and signatures characterize tumor microenvironment and predict outcome in ovarian and endometrial cancersYing Ni, Ahmed Soliman, Amy Joehlin-Price, et al.Gynecologic Oncology Reports|March 17, 2025
Maintenance bevacizumab following chemotherapy is associated with improved survival in patients with advanced and recurrent cervical cancer in a single-institution retrospective studyJohanna Kelley, Meng Yao, Danielle Chau, et al.Gynecologic Oncology|April 26, 2003
Prolonged oral etoposide in recurrent or advanced non-squamous cell carcinoma of the cervix: a Gynecologic Oncology Group studyPeter G Rose, John A Blessing, Richard E Buller, et al.Gynecologic Oncology|August 8, 2006
Radiation therapy with concomitant paclitaxel and cisplatin chemotherapy in cervical carcinoma limited to the pelvis: a phase I/II study of the Gynecologic Oncology GroupPaul A DiSilvestro, Joan L Walker, Astrid Morrison, et al.Gynecologic Oncology|January 28, 2021
Impact of antibiotic treatment on immunotherapy response in women with recurrent gynecologic cancerLaura M Chambers, Chad M Michener, Peter G Rose, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 29, 2023
Phase III Trial of Carboplatin and Paclitaxel Compared With Cisplatin and Paclitaxel in Patients With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group StudyRobert F Ozols, Brian N Bundy, Benjamin E Greer, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 16, 2003
Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group studyRobert F Ozols, Brian N Bundy, Benjamin E Greer, et al.Pageof 22